ADC & cancer drugs stocks
ADC·항암제
What are ADC & cancer drugs stocks in Korea?
The ADC & cancer drugs theme on jonbur groups 11 Korean stocks listed on KOSPI and KOSDAQ, worth ₩95T in total. On Oct 27, 2026 the group moved down 3.83% (weighted by market value); the largest members are Samsung Biologics, Alteogen, Yuhan.
Key facts
- Stocks
- 11
- Total market value
- ₩95T
- Day's move
- −3.83%
- As of
- Oct 27, 2026
- Largest members
- Samsung Biologics, Alteogen, Yuhan
Earnings tracker · 3Q 2026
Reporting season · reports due by Nov 14
Combined, for the companies that have reported, vs the same quarter a year ago
| Company | Reported | Revenue | vs a year ago | Operating profit | vs a year ago | vs last quarter | Op. margin |
|---|---|---|---|---|---|---|---|
| Yuhan | Oct 28Preliminary | ₩586B | +2.8% | ₩35B | +57.8% | −48.0% | 5.9%3.9% |
| Hanmi Pharm | Oct 27Preliminary | ₩377B | +4.2% | ₩38B | −31.3% | −71.2% | 10.0%15.2% |
| Samsung Biologics | Expected around Oct 28 | ||||||
| ABL Bio | Expected around Nov 11 | ||||||
| Eutilex | Expected around Nov 13 | ||||||
| Alteogen | Expected around Nov 14 | ||||||
| LigaChem Biosciences | Expected around Nov 14 | ||||||
| GI Innovation | Expected around Nov 14 | ||||||
| ImmuneOncia Therapeutics | Expected around Nov 14 | ||||||
| Y-Biologics | Expected around Nov 14 | ||||||
| Oncocross | Expected around Nov 14 | ||||||
Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.
Technical breadth
After the close on Oct 27, 2026- Above 20-day average
- 26.7%
- Above 60-day average
- 33.3%
- RSI above 70
- 0%
- RSI below 30
- 13.3%
- 52-week highs
- 0
- 52-week lows
- 0
Index gauge · Short term
Bearish
1 bullish, 1 neutral, 7 bearish
Index gauge · Medium term
Bearish
0 bullish, 1 neutral, 7 bearish
Technical read
The ADC and cancer drugs theme spans 15 Korean members, and only 26.7% of them trade above their 20-day averages while 33.3% sit above their 60-day averages. No member is at a 52-week high, and none is at a 52-week low, though one name's RSI reads 13.3, deep in oversold territory, while no member's RSI reads as overbought. The equal-weighted theme index shows a bearish reading on both short and medium horizons, with its RSI at 43 and price positioned below its cloud.
Written by AI from the indicator values above. Not advice.
Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.
Credit & macro
No notable credit, ELS or macro events for these companies in the last 30 days.
ADC & cancer drugs
−1.40%ADC·항암제
ADC & cancer drugs is a Korean stock-market theme covering antibody-drug conjugates, which link an antibody to a cytotoxic payload to target cancer cells, along with other oncology drug developers and related contract manufacturing and platform technologies. Korean investors tend to group these companies together because the sector is closely tied to biopharma licensing deals with global pharmaceutical firms and to the technology transfer and manufacturing capacity that supports them. Stocks in this theme often move together on news about clinical trial results, international partnerships, or regulatory milestones.
11 companies · 3 up · 2 flat · 6 down
- Traded value
- ₩244B
- Value vs 20-day average
- 0.84×
- Top gainer
- Oncocross +1.97%
- Largest company
- Samsung Biologics ₩64T
Companies in this theme
| Company | Price | Daily | Traded value | Market cap | NPS |
|---|---|---|---|---|---|
Samsung Biologics207940 · KOSPI | ₩1,374,000 | −5.37% | ₩124B | ₩64T | 6.88% |
Alteogen196170 · KOSDAQ | ₩218,500 | 0.00% | ₩52B | ₩15T | 2.68% |
Yuhan000100 · KOSPI | ₩80,000 | −2.08% | ₩16B | ₩5.9T | 6.83% |
Hanmi Pharm128940 · KOSPI | ₩350,500 | −0.57% | ₩26B | ₩4.5T | 9.61% |
LigaChem Biosciences141080 · KOSDAQ | ₩63,900 | −1.54% | ₩12B | ₩2.4T | 4.99% |
ABL Bio298380 · KOSDAQ | ₩40,850 | +0.12% | ₩10B | ₩2.3T | 4.02% |
GI Innovation358570 · KOSDAQ | ₩7,030 | −8.22% | ₩2.5B | ₩454B | 4.07% |
ImmuneOncia Therapeutics424870 · KOSDAQ | ₩2,830 | −0.70% | ₩637M | ₩259B | — |
Y-Biologics338840 · KOSDAQ | ₩10,200 | +0.99% | ₩834M | ₩157B | 0.17% |
Oncocross382150 · KOSDAQ | ₩3,110 | +1.97% | ₩99M | ₩41B | — |
Eutilex263050 · KOSDAQ | ₩959 | 0.00% | ₩0 | ₩35B | 0.74% |
Source: KRX statistical information